Your browser doesn't support javascript.
Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome.
Valentini, Diletta; Cotugno, Nicola; Scoppola, Vittorio; Di Camillo, Chiara; Colagrossi, Luna; Manno, Emma Concetta; Perno, Carlo Federico; Russo, Cristina; Palma, Paolo; Rossi, Paolo; Villani, Alberto.
  • Valentini D; Pediatric Unit, Pediatric Emergency Department (DEA), Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Cotugno N; Clinical & Research Unit of Clinical Immunology and Vaccinology, Academic Department of Pediatrics (DPUO), Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Scoppola V; Chair of Pediatrics, Department of Systems Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
  • Di Camillo C; The School of Pediatrics, Tor Vergata University, 00133 Rome, Italy.
  • Colagrossi L; Pediatric Unit, Pediatric Emergency Department (DEA), Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Manno EC; Department of Laboratories, Bambino Gesù Children's Hospital, 00165 Rome, Italy.
  • Perno CF; Clinical & Research Unit of Clinical Immunology and Vaccinology, Academic Department of Pediatrics (DPUO), Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Russo C; Department of Laboratories, Bambino Gesù Children's Hospital, 00165 Rome, Italy.
  • Palma P; Unit of Microbiology and Diagnostic Immunology, Department of Laboratories, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Rossi P; Clinical & Research Unit of Clinical Immunology and Vaccinology, Academic Department of Pediatrics (DPUO), Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
  • Villani A; Chair of Pediatrics, Department of Systems Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
J Clin Med ; 11(3)2022 Jan 28.
Article in English | MEDLINE | ID: covidwho-1667210
ABSTRACT
We aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in young people with Down syndrome (DS), and to compare their humoral immune response with those of the healthy controls (HC). Individuals with DS and HC received the BNT162b2 vaccine. Longitudinal blood samples were collected on the day of vaccination, twenty-one days after the first dose, seven days after the second dose, and six months after the first dose. Both the local and systemic adverse events reported by participants were mild. Pain at the injection site was the most reported local adverse event, while fever was the systemic adverse event. Humoral responses showed a significant increase of anti-S and anti-S trimeric antibody (Ab) levels after both doses of vaccine in both groups. In comparison with HC, Ab levels in individuals with DS were similar at T21, but significantly lower, both in terms anti-S and anti-S trimeric, at T28 (respectively p = 0.0003 and p = 0.0001). At T180 both groups showed a significant reduction of anti-S trimeric Ab levels compared to T28 (p = 0.0004 and p < 0.0001 for DS and HC, respectively). Individuals with DS exhibit a good humoral response to the BNT162b2 vaccine; however, similarly to in HC, the immune response wanes over time.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Jcm11030694

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Jcm11030694